CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that the Company will participate in two upcoming investor conferences.
- Obi Greenman, Cerus’ president and chief executive officer is scheduled to attend BTIG’s Annual Healthcare Conference in Snowbird Utah on Wednesday, February 27, 2019.
- Obi Greenman and Kevin Green, Cerus’ vice president finance and chief financial officer, are scheduled to present a corporate update at Cowen’s 39th Annual Healthcare Conference in Boston, Massachusetts on Tuesday, March 12, 2019 at 10:00 a.m. ET.
A live webcast of the presentation from Cowen’s 39th Annual Healthcare Conference will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.